These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

231 related articles for article (PubMed ID: 24564812)

  • 41. Adherence and persistence to prescribed medication therapy among Medicare part D beneficiaries on dialysis: comparisons of benefit type and benefit phase.
    Park H; Rascati KL; Lawson KA; Barner JC; Richards KM; Malone DC
    J Manag Care Spec Pharm; 2014 Aug; 20(8):862-76. PubMed ID: 25062080
    [TBL] [Abstract][Full Text] [Related]  

  • 42. Effects of Medicare Part D coverage gap on medication and medical treatment among elderly beneficiaries with depression.
    Zhang Y; Baik SH; Zhou L; Reynolds CF; Lave JR
    Arch Gen Psychiatry; 2012 Jul; 69(7):672-9. PubMed ID: 22752233
    [TBL] [Abstract][Full Text] [Related]  

  • 43. The Effect of Medicare Part D on Pharmaceutical Prices and Utilization.
    Duggan M; Morton FS
    Am Econ Rev; 2010 Mar; 100(1):590-607. PubMed ID: 29508975
    [No Abstract]   [Full Text] [Related]  

  • 44. Coverage for hepatitis C drugs in Medicare Part D.
    Jung JK; Feldman R; Cheong C; Du P; Leslie D
    Am J Manag Care; 2016 May; 22(6 Spec No.):SP220-6. PubMed ID: 27266952
    [TBL] [Abstract][Full Text] [Related]  

  • 45. Medicare Spending and Potential Savings on Brand-Name Drugs With Available Generic Substitutes Excluded by 2 Large Pharmacy Benefit Managers, 2012 Through 2015.
    Egilman AC; Wallach JD; Ross JS; Dhruva SS
    JAMA Intern Med; 2018 Apr; 178(4):567-569. PubMed ID: 29340562
    [TBL] [Abstract][Full Text] [Related]  

  • 46. Assessment of Hypothetical Out-of-Pocket Costs of Guideline-Recommended Medications for the Treatment of Older Adults With Multiple Chronic Conditions, 2009 and 2019.
    Zhou T; Liu P; Dhruva SS; Shah ND; Ramachandran R; Berg KM; Ross JS
    JAMA Intern Med; 2022 Feb; 182(2):185-195. PubMed ID: 34982097
    [TBL] [Abstract][Full Text] [Related]  

  • 47. Minimizing out-of-pocket prescription drug costs for Medicare beneficiaries: not just 'a drop in the bucket'.
    Patel RA; Vo KA; Chu T; Wang K; Lu S; Woelfel JA; Carr-Lopez SM; Galal SM
    J Am Pharm Assoc (2003); 2014; 54(6):604-9. PubMed ID: 25379981
    [TBL] [Abstract][Full Text] [Related]  

  • 48. Closing the Medicare Doughnut Hole: Changes in Prescription Drug Utilization and Out-of-Pocket Spending Among Medicare Beneficiaries With Part D Coverage After the Affordable Care Act.
    Bonakdar Tehrani A; Cunningham PJ
    Med Care; 2017 Jan; 55(1):43-49. PubMed ID: 27547949
    [TBL] [Abstract][Full Text] [Related]  

  • 49. Impact of brand drug discount cards on private insurer, government and patient expenditures.
    Law MR; Chan FKI; Harrison M; Worthington HC
    CMAJ; 2019 Nov; 191(45):E1237-E1241. PubMed ID: 31712357
    [TBL] [Abstract][Full Text] [Related]  

  • 50. Utilization of Generic Cardiovascular Drugs in Medicare's Part D Program.
    Ma I; Tisdale RL; Vail D; Heidenreich PA; Sandhu AT
    Circ Cardiovasc Qual Outcomes; 2021 Dec; 14(12):e007559. PubMed ID: 34879702
    [TBL] [Abstract][Full Text] [Related]  

  • 51. Impact of Cost Sharing on Therapeutic Substitution: The Story of Statins in 2006.
    Li P; Schwartz JS; Doshi JA
    J Am Heart Assoc; 2016 Nov; 5(11):. PubMed ID: 27836822
    [TBL] [Abstract][Full Text] [Related]  

  • 52. Factors Associated With Prescriptions for Branded Medications in the Medicare Part D Program.
    Socal MP; Bai G; Anderson GF
    JAMA Netw Open; 2021 Mar; 4(3):e210483. PubMed ID: 33651110
    [TBL] [Abstract][Full Text] [Related]  

  • 53. Association between Higher Generic Drug Use and Medicare Part D Star Ratings: An Observational Analysis.
    Hohmann N; Hansen R; Garza KB; Harris I; Kiptanui Z; Qian J
    Value Health; 2018 Oct; 21(10):1186-1191. PubMed ID: 30314619
    [TBL] [Abstract][Full Text] [Related]  

  • 54. Savings from drug discount cards: relief for Medicare beneficiaries?
    Cubanski J; Frank RG; Epstein AM
    Health Aff (Millwood); 2004; Suppl Web Exclusives():W4-198-209. PubMed ID: 15451980
    [TBL] [Abstract][Full Text] [Related]  

  • 55. Variation in generic dispensing rates in Medicare Part D.
    Buttorff C; Xu Y; Joyce G
    Am J Manag Care; 2020 Nov; 26(11):e355-e361. PubMed ID: 33196286
    [TBL] [Abstract][Full Text] [Related]  

  • 56. Medicare prescription drug plan coverage of pharmacotherapies for opioid and alcohol dependence in WA.
    Kennedy J; Dipzinski A; Roll J; Coyne J; Blodgett E
    Drug Alcohol Depend; 2011 Apr; 114(2-3):201-6. PubMed ID: 21134724
    [TBL] [Abstract][Full Text] [Related]  

  • 57. Health Costs and Outcomes Associated with Medicare Part D Prescription Drug Cost-Sharing in Beneficiaries on Dialysis.
    Park H; Rascati KL; Lawson KA; Barner JC; Richards KM; Malone DC
    J Manag Care Spec Pharm; 2015 Oct; 21(10):956-64. PubMed ID: 26402394
    [TBL] [Abstract][Full Text] [Related]  

  • 58. Secular Trends in the Cost of Immunosuppressants after Solid Organ Transplantation in the United States.
    Helmuth ME; Liu Q; Turenne MN; Park JM; Oguntimein M; Dutcher SK; Balkrishnan R; Sharma P; Zee J; Leichtman AB; Smith AR
    Clin J Am Soc Nephrol; 2019 Mar; 14(3):421-430. PubMed ID: 30819667
    [TBL] [Abstract][Full Text] [Related]  

  • 59. Association of Industry Payments to Physicians With the Prescribing of Brand-name Statins in Massachusetts.
    Yeh JS; Franklin JM; Avorn J; Landon J; Kesselheim AS
    JAMA Intern Med; 2016 Jun; 176(6):763-8. PubMed ID: 27159336
    [TBL] [Abstract][Full Text] [Related]  

  • 60. Five-year examination of utilization and drug cost outcomes associated with benefit design changes including reference pricing for proton pump inhibitors in a state employee health plan.
    Johnson JT; Neill KK; Davis DA
    J Manag Care Pharm; 2011 Apr; 17(3):200-12. PubMed ID: 21434697
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 12.